Tepotinib hydrochloride

Drug Overview

Tepotinib hydrochloride is an oral, highly selective, Targeted Therapy classified as a small-molecule inhibitor. It is designed to treat specific subsets of non-small cell lung cancer (NSCLC) that harbor a crucial genetic alteration, providing a precision medicine approach for advanced disease.

• Generic Name: Tepotinib hydrochloride
• US Brand Names: TEPMETKO®
• Drug Class: Kinase Inhibitor; Targeted Therapy; Smart Drug
• Route of Administration: Oral
• FDA Approval Status: Approved

What Is It and How Does It Work? (Mechanism of Action)

Tepotinib is a potent and highly selective inhibitor of the Mesenchymal-Epithelial Transition (MET) receptor tyrosine kinase. Its mechanism targets the underlying driver mutation responsible for tumor growth and survival in specific types of cancer.

• Molecular Target: Tepotinib specifically targets the adenosine triphosphate (ATP)-binding pocket of the MET receptor tyrosine kinase.
• Targeted Alteration: The drug is indicated for non-small cell lung cancer (NSCLC) patients whose tumors have a mutation leading to MET exon 14 skipping. This genetic alteration results in a dysfunctional MET receptor that is overactive or persistently signaling, driving cancer cell proliferation, survival, and motility.
• Mechanism of Inhibition: By binding to the MET receptor’s ATP-binding pocket, Tepotinib prevents the phosphorylation of the receptor. This action effectively blocks the initiation of downstream signaling pathways, such as the RAS/MAPK, PI3K/AKT, and STAT pathways, which are critical for oncogenic processes.
• Resulting Cellular Impact: The inhibition of the hyperactivated MET pathway leads to:
  • Reduced cancer cell proliferation.
  • Increased tumor cell apoptosis (programmed cell death).
  • Inhibition of angiogenesis (formation of new blood vessels).
  • Decreased tumor invasiveness and metastatic potential.

FDA Approved Clinical Indications

• Oncological Uses:
  • Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping alteration.
  • Patients must be diagnosed using an FDA-approved companion diagnostic test.
• Non-oncological Uses:
  • None currently approved.

Dosage and Administration Protocols

Tepotinib is administered orally once daily.

Clinical Efficacy and Research Results

The efficacy of Tepotinib was established primarily through the VISION trial (NCT02864992), a multicohort, open-label, Phase 2 study of patients with advanced NSCLC with MET exon 14 skipping.

• Overall Response Rate (ORR): Current data (2020-2025 context) from the VISION trial showed a high objective response rate in the target population. For treatment-naïve and previously treated patients, the ORR was reported to be approximately 43% to 51%.
• Duration of Response (DOR): The responses achieved with Tepotinib were durable. The median duration of response (DOR) for responders was typically reported to be around 10.8 to 16.5 months, which is clinically significant in this difficult-to-treat patient population.
• Effects on Disease Progression: The benefit was consistent across various patient characteristics, including those who had prior immunotherapy or chemotherapy. The demonstrated efficacy confirms the drug’s role as a potent targeted agent for the MET exon 14 skipping alteration, representing improved outcomes compared to standard non-targeted therapies.
• Central Nervous System (CNS) Activity: Tepotinib showed evidence of activity in patients with brain metastases, a common site of progression in NSCLC, suggesting it may penetrate the blood-brain barrier to some extent.

Safety Profile and Side Effects

Tepotinib’s safety profile is consistent with other small-molecule kinase inhibitors.

Critical Warning (Interstitial Lung Disease/Pneumonitis)

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal cases of ILD/pneumonitis have occurred in patients treated with Tepotinib. Treatment must be immediately withheld upon suspicion of ILD and permanently discontinued if confirmed.

Common Side Effects (>10%)

• General: Peripheral edema (swelling, particularly in the lower extremities) is the most common side effect.
• Gastrointestinal: Nausea, diarrhea, constipation.
• Metabolic: Hypoalbuminemia (low blood protein), elevated blood creatinine, and elevated liver enzymes (AST/ALT).
• Respiratory: Dyspnea (shortness of breath).

Serious Adverse Events

• Interstitial Lung Disease (ILD)/Pneumonitis: Requires immediate symptom recognition and management. Patients must be monitored for new or worsening respiratory symptoms.
• Hepatotoxicity: Severe liver injury, including drug-induced liver injury, can occur. Treatment may need to be interrupted or discontinued based on liver enzyme elevation.
• Fluid Retention (Edema): Severe peripheral and facial edema requiring diuretic intervention or dose modification.

Management Strategies:

• Edema: Low-sodium diet, leg elevation, and prescription of diuretics (e.g., furosemide) for management of peripheral edema.
• Diarrhea: Use of antidiarrheal agents (e.g., loperamide) and monitoring for dehydration.
• Hepatotoxicity: Close monitoring of LFTs every 2 weeks for the first 3 months, then monthly.

Research Areas

Tepotinib’s selective mechanism positions it as a key focus in oncology research:

• Combination Therapies: Research is exploring the combination of Tepotinib with standard chemotherapies or newer immunotherapies (e.g., PD-1/PD-L1 inhibitors) to overcome resistance mechanisms or enhance therapeutic effects in MET-altered cancers.
• Liquid Biopsy and Resistance: Significant work is being done to use liquid biopsy (blood-based) techniques to monitor MET exon 14 skipping alterations and track the emergence of secondary resistance mutations, which may guide subsequent treatment choices.
• Other Cancers: Investigations are ongoing into the activity of Tepotinib in other cancers where MET alterations (amplification or fusions) are implicated, such as renal cell carcinoma and gastric cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to Be Performed

• Genetic Testing: Confirmation of the MET exon 14 skipping alteration in tumor tissue or plasma using an FDA-approved companion diagnostic test is mandatory before starting therapy.
• Labs: Baseline Complete Blood Count (CBC), Liver Function Tests (LFTs), Renal Function Tests (RFTs), and albumin levels.
• Imaging: Baseline chest imaging (CT scan) to establish a reference for disease monitoring.

Precautions During Treatment

• ILD Monitoring: Patients must be educated to report any new or worsening cough, shortness of breath, or fever immediately.
• Fluid Balance: Monitor for the development or worsening of peripheral edema.
• Drug Interactions: Tepotinib is a substrate of CYP3A4 and a weak inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inducers (e.g., rifampin) or strong inhibitors should be avoided or managed with caution.

Do’s and Don’ts

Do take the 450 mg dose once daily with food.

Do use effective, non-hormonal contraception during treatment and for at least one week after the last dose.

Do notify your healthcare team immediately if you experience new or worsening breathing problems, swelling, or yellowing of the skin/eyes.

Don’t chew, crush, or split the tablets.

Don’t take a missed dose if the next dose is less than 8 hours away.

Don’t use strong CYP3A4 inducers (e.g., certain antibiotics or herbal supplements like St. John’s Wort) without consulting your physician.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It summarizes medical and clinical data pertaining to tepotinib hydrochloride. It does not constitute and should not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Dosing, protocols, and clinical decisions must be customized to the individual patient’s condition and comply with local regulatory guidelines. Always consult with a qualified oncologist or healthcare professional regarding specific medical guidance.